The Company has more than 45 proprietary and partnered product candidates in development
Ablynx participates and presents at IR and scientific conferences
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC.15 September 2016
ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM GAM HOLDING AG, GAM INTERNATIONAL MANAGEMENT LIMITED AND TAUBE HODSON STONEX PARTNERS LLP06 September 2016
ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE25 August 2016
TITAN study - Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura